登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
ClinicalTrials.gov 上登记的一项冠心病开放试验,由Shenyang Northern Hospital牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07362966,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
40 岁 至 85 岁;性别:不限
登记记录的入选字段
Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;
排除标准第 12 条
Abnormal liver function (ALT >3 times the upper limit of normal range) at randomization;
排除标准第 5 条
Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated eGFR <45 mL/min/1.73 m²) at randomization;
排除标准第 6 条
Hematologic abnormalities: anemia (hemoglobin <100g/L), thrombocytopenia (platelet count <100×109/L) or leukopenia (white blood cell <3×109/L) at randomization;
排除标准第 7 条
Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics;
排除标准第 13 条
Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception;
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07362966,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 40-85 years; Patients with recent hospitalization for documented ACS (the index event occurring 30-90 days before randomization) and meeting all of the following: During the index hospitalization, patients underwent either PCI or diagnostic coronary angiography alone, At least one non-culprit coronary lesion with 30%-70% diameter stenosis by visual estimation on coronary angiography, Clinically stable throughout the screening period, Receiving standard of care therapy for ACS in accordance with national guidelines, Peripheral blood DNA available for targeted sequencing, with results demonstrating either TET2-CHIP or no CHIP-associated variants; Written informed consent.排除标准:Exclusion Criteria:
Prior coronary artery bypass grafting (CABG) before documented ACS; Other clinically significant cardiovascular diseases, including moderate-to-severe valvular heart disease (moderate or severe), heart failure (NYHA class III-IV), or atrial fibrillation; Non-culprit coronary anatomy (e.g., marked tortuosity, bifurcation lesions, or small vessels <1.5 mm in diameter) deemed to preclude plaque assessment by CCTA; Planned PCI or CABG; Abnormal liver function (ALT >3 times the upper limit of normal range) at randomization; Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated eGFR <45 mL/min/1.73 m²) at randomization; Hematologic abnormalities: anemia (hemoglobin <100g/L), thrombocytopenia (platelet count <100×109/L) or leukopenia (white blood cell <3×109/L) at randomization; Inflammatory bowel disease (Crohn's or ulcerative colitis) or active diarrhea; Symptomatic peripheral neuropathy, pre-existing progressive neuromuscular disease or creatine kinase (CK) level > 3 times the upper limit of normal range as measured within the past 30 days and determined to be non-transient through repeat testing; Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception; Any contraindication, known allergy or intolerance to colchicine; Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications; Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics; Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs; History of malignancy (hematologic or solid-tumor); History of transplantation (hematopoietic stem cell or solid-organ); Significant radiation exposure (≥40 mSv) within the past 12 months; Known hypersensitivity to iodinated contrast media or uncontrolled active hyperthyroidism; Current enrollment in another clinical trial; A predicted life expectancy < 1 year; Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
引自 ClinicalTrials.gov, NCT07362966, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07362966,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。